HAVN Life Sciences Inc.
HAVLF · OTC
4/30/2022 | 4/30/2021 | 4/30/2020 | |
|---|---|---|---|
| Valuation | |||
| PEG Ratio | 0.01 | -0.00 | 0.00 |
| FCF Yield | -96.68% | -13.50% | -0.11% |
| EV / EBITDA | -1.01 | -4.61 | 0.00 |
| Quality | |||
| ROIC | -277.90% | -222.27% | 8.72% |
| Gross Margin | 32.44% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.35 | 0.34 | 1.85 |
| Growth | |||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% |
| Free Cash Flow Growth | 23.69% | -13,836.69% | 0.00% |
| Safety | |||
| Net Debt / EBITDA | 0.09 | 0.60 | 0.00 |
| Interest Coverage | -152.94 | -1,734.96 | 0.00 |
| Efficiency | |||
| Inventory Turnover | 0.16 | 12.82 | 0.00 |
| Cash Conversion Cycle | 1,816.96 | -13.91 | 0.00 |